Clinical trials: QTc Interval
Hepatic Fibrosis
QTc Assessment in a Single-Dose Study of Hydronidone Capsules
This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone…
- Trial name
- NCT07263152
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
QT Intervals Changes, QTc Intervals Changes
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
The primary objective of this study is to assess the effect of a single therapeutic (50 mg) oral dose of omecamtiv mecarbil (OM) on the QT interval / QT interval corrected for heart rate (QTc), relative to placebo, in healthy…
- Trial name
- NCT04175808
- Testing
- Omecamtiv Mecarbil (OM), Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Postoperative Pain
Phase 1 Thorough QT Study in Young Healthy Volunteers
A reduction in the postoperative need for opioids to enhance the recovery process and increase patient postoperative satisfaction.
- Trial name
- TQT (NCT00485667)
- Testing
- SKY0402, Moxifloxacin 400mg
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pacira Pharmaceuticals, Inc
Cardiovascular Diseases
Evaluation of Energy Drinks on Electrocardiographic, Vascular and Hematologic Parameters in Healthy Volunteers
This study will determine the cardiovascular effects of energy drink consumption in healthy individuals through electrocardiogram (ECG), central blood pressure assessment, and ROTEM® analysis.
- Trial name
- NCT03021616
- Testing
- energy drink, Moxifloxacin 400mg
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- David Grant U.S. Air Force Medical Center
Dyslipidemia
A Thorough Corrected QT Interval Trial
The purpose of this study is to determine the effects of K-877 on ECG parameters with a focus on cardiac repolarization compared with placebo in healthy adult subjects.
- Trial name
- NCT02073084
- Testing
- K-877 Low Dose, Moxifloxacin, K-877 High Dose
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Healthy
Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval
This Study compares two ZD4054 (Zibotentan) doses (10mg and 30mg) with a placebo and a positive control to look at ZD4054 (Zibotentan)'s effect on the ECG of Healthy Volunteer
- Trial name
- NCT00713336
- Testing
- ZD4054, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
The study will assess the corrected QT (QTc) effects (electrocardiogram [ECG]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative…
- Trial name
- NCT05293171
- Testing
- 2 mg/kg BL-8040, 400 mg Moxifloxacin (1x400 mg tablet)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- BioLineRx, Ltd.
RSV Infection, QTc Interval
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
The purpose of the study is to assess the effect of a therapeutic and supratherapeutic dose of zelicapavir on the corrected cardiac QT interval relative to a placebo and positive control in healthy participants.
- Trial name
- NCT06601192
- Testing
- zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Rheumatoid Arthritis
A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart
This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart.
- Trial name
- NCT00887770
- Testing
- AZD5672, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers
Study to investigate the effect of BI 1744 CL on the QT/QTc interval of the ECG (electrocardiogram) in comparison to placebo
- Trial name
- NCT02172144
- Testing
- BI 1744 CL solution for inhalation, Moxifloxacin (Avalox®)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects
Administration of a single 50 mg or 200 mg dose of tigecycline will not cause a change in QT/QTc intervals.
- Trial name
- NCT01287793
- Testing
- tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pfizer
Human Volunteers
TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.
This is a study to evaluate the effect of TMC278 25 mg daily on the QT/QTc interval (heart conduction and heart rhythm) in healthy volunteers.
- Trial name
- NCT00744809
- Testing
- TMC278; Moxifloxacin; Efavirenz
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Cardiac Repolarization in Healthy Subjects
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
- Trial name
- NCT06161220
- Testing
- Carbidopa capsule, Moxifloxacin Tablets, USP
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Impax Laboratories, LLC
Healthy
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
The purpose of this study is to assess the effects on placebo-corrected change from baseline QT interval corrected for individual heart rate (QTcI) of JNJ-64565111 close to steady state on Day 26 and on electrocardiogram…
- Trial name
- NCT03606057
- Testing
- JNJ-64565111, Moxifloxacin
- Where
- United States
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)
The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.
- Trial name
- NCT07266818
- Testing
- MK-1167
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Qt Interval, Variation in
Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers
The study designed to determine the effect induced by WCK 2349 on the QT interval. The study will be conducted in two parts: 1) to determine the supratherapeutic dose; and 2) to assess the safety of high doses of single-dose…
- Trial name
- NCT02217930
- Testing
- WCK 2349, Moxifloxacin
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wockhardt
Malaria, Vivax
Tafenoquine Thorough QTc Study in Healthy Subjects
This will be a randomized, single-blind, placebo controlled, parallel group study. Approximately 260 subjects will be enrolled in five groups.
- Trial name
- NCT01928914
- Testing
- Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer
A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval
This is a 2 part study to evaluate the safety and tolerability of supra-therapeutic doses of RO4602522 (Part A); and to investigate the effect of RO4602522 on the QTcF interval in healthy volunteers (Part B).
- Trial name
- NCT02104648
- Testing
- RO4602522, moxifloxacin
- Where
- United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Ventricular Repolarization
A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects
This study is conducted to evaluate the effectiveness of DIC075V on ventricular repolarization in healthy subjects compared to placebo after a single dose of DIC075V administered intravenously (IV) and to evaluate ECG assay…
- Trial name
- NCT01812538
- Testing
- DIC075V
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Paroxysmal Nocturnal Hemoglobinuria
To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects
A Concentration-QT Interval Correction (C-QTc) study of MY008211A Tablets in Healthy Subjects
- Trial name
- NCT06543459
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd